Antimicrobial properties of Lactobacillus cell-free supernatants against multidrug-resistant urogenital pathogens.
Lactobacilli
MDR-urogenital infection
antimicrobial activity
supernatants
vaginal probiotics
Journal
MicrobiologyOpen
ISSN: 2045-8827
Titre abrégé: Microbiologyopen
Pays: England
ID NLM: 101588314
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
revised:
22
01
2021
received:
31
10
2020
accepted:
29
01
2021
entrez:
10
5
2021
pubmed:
11
5
2021
medline:
24
11
2021
Statut:
ppublish
Résumé
The healthy vaginal microbiota is dominated by Lactobacillus spp., which provide an important critical line of defense against pathogens, as well as giving beneficial effects to the host. We characterized L. gasseri 1A-TV, L. fermentum 18A-TV, and L. crispatus 35A-TV, from the vaginal microbiota of healthy premenopausal women, for their potential probiotic activities. The antimicrobial effects of the 3 strains and their combination against clinical urogenital bacteria were evaluated together with the activities of their metabolites produced by cell-free supernatants (CFSs). Their beneficial properties in terms of ability to interfere with vaginal pathogens (co-aggregation, adhesion to HeLa cells, biofilm formation) and antimicrobial activity mediated by CFSs were assessed against multidrug urogenital pathogens (S. agalactiae, E. coli, KPC-producing K. pneumoniae, S. aureus, E. faecium VRE, E. faecalis, P. aeruginosa, P. mirabilis, P. vulgaris, C. albicans, C. glabrata). The Lactobacilli tested exhibited an extraordinary ability to interfere and co-aggregate with urogenital pathogens, except for Candida spp., as well as to adhere to HeLa cells and to produce biofilm in the Lactobacillus combination. Lactobacillus CFSs and their combination revealed a strong bactericidal effect on the multidrug resistant indicator strains tested, except for E. faecium and E. faecalis. The antimicrobial activity was maintained after heat treatment but decreased after enzymatic treatment. All Lactobacilli showed lactic dehydrogenase activity and production of D- and L-lactic acid isomers on Lactobacillus CFSs, while only 1A-TV and 35A-TV released hydrogen peroxide and carried helveticin J and acidocin A bacteriocins. These results suggest that they can be employed as a new vaginal probiotic formulation and bio-therapeutic preparation against urogenital infections. Further, in vivo studies are needed to evaluate human health benefits in clinical situations.
Identifiants
pubmed: 33970542
doi: 10.1002/mbo3.1173
pmc: PMC8483400
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1173Informations de copyright
© 2021 The Authors. MicrobiologyOpen published by John Wiley & Sons Ltd.
Références
Eur J Clin Microbiol Infect Dis. 2015 Dec;34(12):2377-83
pubmed: 26385346
J Appl Microbiol. 2003;94(6):981-7
pubmed: 12752805
Appl Environ Microbiol. 2003 Oct;69(10):6056-63
pubmed: 14532062
Microb Ecol Health Dis. 2016 Aug 12;27:30484
pubmed: 27527701
Meat Sci. 2014 Jan;96(1):295-303
pubmed: 23933630
Sci Rep. 2019 Mar 4;9(1):3355
pubmed: 30833631
Int J Food Microbiol. 2002 Feb 5;72(3):215-24
pubmed: 11845820
Int J Health Sci (Qassim). 2019 Mar-Apr;13(2):48-55
pubmed: 30983946
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3951-6
pubmed: 18319345
BMC Infect Dis. 2011 Jul 19;11:200
pubmed: 21771337
J Appl Microbiol. 2014 May;116(5):1297-307
pubmed: 24552173
Arch Microbiol. 2016 Sep;198(7):689-700
pubmed: 27146055
Microbiology (Reading). 2016 Jul;162(7):1195-1207
pubmed: 27154285
Appl Environ Microbiol. 2007 Nov;73(21):6768-75
pubmed: 17827316
BMC Infect Dis. 2013 Jan 26;13:43
pubmed: 23351177
Appl Environ Microbiol. 2003 Nov;69(11):6908-22
pubmed: 14602655
Res Microbiol. 2017 Nov - Dec;168(9-10):782-792
pubmed: 28435139
Appl Environ Microbiol. 2019 Jan 23;85(3):
pubmed: 30504209
Am J Med Sci. 2012 Jan;343(1):2-9
pubmed: 22143133
Eur J Obstet Gynecol Reprod Biol. 2006 Nov;129(1):69-76
pubmed: 16814920
Infect Drug Resist. 2018 Oct 10;11:1645-1658
pubmed: 30349322
Int J Mol Sci. 2019 May 23;20(10):
pubmed: 31126033
Nat Rev Microbiol. 2011 Jan;9(1):27-38
pubmed: 21113182
Front Microbiol. 2017 Feb 07;8:166
pubmed: 28223974
Front Immunol. 2020 Jan 09;10:3019
pubmed: 31998306
Front Microbiol. 2016 Dec 08;7:1936
pubmed: 28008325
Sex Transm Dis. 2004 Jul;31(7):393-400
pubmed: 15215693
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4680-7
pubmed: 20534435
J Med Microbiol. 2014 May;63(Pt 5):685-696
pubmed: 24523160
Mil Med Res. 2016 Feb 13;3:4
pubmed: 26877884
J Microbiol Immunol Infect. 2008 Dec;41(6):469-77
pubmed: 19255690
Front Microbiol. 2017 May 19;8:876
pubmed: 28579977
Curr Pharm Biotechnol. 2018;19(15):1241-1247
pubmed: 30636598
PLoS One. 2014 Aug 22;9(8):e105998
pubmed: 25148517
Microbiome. 2018 Feb 06;6(1):29
pubmed: 29409534
Arch Gynecol Obstet. 2014 Mar;289(3):479-89
pubmed: 24170161
PLoS One. 2015 Jun 22;10(6):e0131220
pubmed: 26098675
AMB Express. 2018 Jan 24;8(1):10
pubmed: 29368243
BJOG. 2007 Nov;114(11):1402-7
pubmed: 17877778
Nucleic Acids Res. 1997 Sep 1;25(17):3389-402
pubmed: 9254694
BMC Microbiol. 2019 Oct 30;19(1):237
pubmed: 31666014
J Physiol. 2017 Jan 15;595(2):451-463
pubmed: 27373840
J Appl Microbiol. 2002;93(5):884-93
pubmed: 12392537
Res Microbiol. 2017 Nov - Dec;168(9-10):845-858
pubmed: 28502874
J Food Prot. 2001 Dec;64(12):2007-14
pubmed: 11770631
Sci Rep. 2019 Feb 27;9(1):2900
pubmed: 30814593
Front Physiol. 2015 Mar 25;6:81
pubmed: 25859220
FEMS Microbiol Rev. 2021 Jan 8;45(1):
pubmed: 32876664
FEMS Immunol Med Microbiol. 2012 Jun;65(1):23-31
pubmed: 22243526
N Am J Med Sci. 2011 Apr;3(4):185-92
pubmed: 22540089
J Infect Dis. 2005 Aug 1;192(3):394-8
pubmed: 15995952
J Clin Microbiol. 1989 Feb;27(2):251-6
pubmed: 2915019
Appl Environ Microbiol. 1995 Mar;61(3):1061-7
pubmed: 7793908